Answers are grounded in this paper and cite their sources.
Advances in antiretroviral therapy for human immunodeficiency virus (HIV) have led to reductions in HIV-related morbidity and mortality. Although antiretroviral therapy has shown success in suppressing viral loads, it does not adequately restore the immune system in all individuals infected with HIV. In light of this incomplete success, interleukin (IL)-2 is being evaluated as adjunctive therapy to antiretroviral therapy. The agent has demonstrated mixed yet promising results in restoring immune function in patients who are HIV positive.
No takes yet. Share an insight, caveat, or question.
Anaya et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: